Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) FCF Margin (2016 - 2025)

Historic FCF Margin for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to 35.86%.

  • Anaptysbio's FCF Margin fell 21300.0% to 35.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 96.01%, marking a year-over-year increase of 848200.0%. This contributed to the annual value of 148.66% for FY2024, which is 5601300.0% up from last year.
  • Per Anaptysbio's latest filing, its FCF Margin stood at 35.86% for Q3 2025, which was down 21300.0% from 180.94% recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's FCF Margin ranged from a high of 43.64% in Q2 2021 and a low of 2503.96% during Q4 2021
  • Its 5-year average for FCF Margin is 725.76%, with a median of 267.74% in 2024.
  • As far as peak fluctuations go, Anaptysbio's FCF Margin plummeted by -25660700bps in 2021, and later surged by 22867600bps in 2022.
  • Over the past 5 years, Anaptysbio's FCF Margin (Quarter) stood at 2503.96% in 2021, then surged by 91bps to 217.2% in 2022, then plummeted by -77bps to 384.55% in 2023, then surged by 30bps to 267.74% in 2024, then surged by 87bps to 35.86% in 2025.
  • Its FCF Margin stands at 35.86% for Q3 2025, versus 180.94% for Q2 2025 and 38.66% for Q1 2025.